UC Davis CTSC supported cellular therapy study improves Duchenne muscular dystrophy
Image
Image Credit
UC Davis Health Public Affairs and Marketing
Organization
Caption
Dr. Craig McDonald examing a kid with Duchenne muscular distrophy
A clinical trial at UC Davis Health and six other sites showed that a cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy (DMD), a rare genetic disorder causing muscle loss and physical impairments in young people.
Submitted by Cheryl Busman on Thursday, March 17, 2022 - 13:03.
CTSA Program In Action Goals
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials